Immunome Inc.
IMNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001472012
In the last 90 days, Immunome Inc. insiders filed 0 open-market purchases and 7 sales; 202 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Immunome Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 35 | 57 | +22 |
| Shares | 2.36M | 21.5M | +19.1M (+809.4%) |
| Value | $19.7M | $229.9M | +$210.3M (+1,070.2%) |
New holders (27)
Institutions that held Immunome Inc. at the end of Q4 2023 but not at the end of Q3 2023.
Sold out (5)
Institutions that held Immunome Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Bank of Montreal | 92,593 | $692.6K |
| Schonfeld Strategic Advisors LLC | 18,201 | $152.0K |
| Wealth Architects, LLC | 11,110 | $92.8K |
| Dorsey Wright & Associates | 3,100 | $25.9K |
| UBS Group AG | 14 | $117 |